Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54

• DOI: 10.1161/circ.132.suppl_3.19642
• Publication Date: 2022-03-19T21:52:40Z
• Authors: Marc P Bonaca; Robert F Storey; Pierre Theroux; P. Gabriel Steg; Deepak L Bhatt; KyungAh Im; Giulia Magnani; Ton Oude Ophuis; Mikhail Ruda; Alexander Parkhom...; Daniel Isaza; Gabriel Kamensky; Assen Goudev; Dayi Hu; Gilles Montalescot; Eva C Jensen; Peter Held; Eugene Braunwald; Marc S Sabatine
• Keywords: TIMI; Stroke; Clinical endpoint

Objectives: Ticagrelor reduced the risk of CV death, MI or stroke in stable patients with prior PEGASUS-TIMI 54. We investigated consistency ticagrelor’s efficacy and safety over time quantified magnitude benefit who tolerated ticagrelor for first year, analogous to clinical situation extending therapy after 1 year. Methods: 54 randomized pts a (median 1.7 yrs randomization) 90 mg twice daily, 60 daily placebo. The rate CVD/MI/stroke TIMI major bleeding were analyzed pooled doses compared placebo year observation then as landmark analysis beginning all alive at that point. Results: 21,162 followed median 33 months, 29% ≥5 from their most recent by end trial. arm remained roughly constant trial ∼3%/y. significantly both (HR 0.84, 95% CI 0.71-0.98, P=0.029, Figure Left) one 0.85, 0.74-0.97, P=0.017, Right), event curves continuing diverge through follow-up. Major was increased within 3.46, 2.07-5.77) but numerically less so 2.06, 1.43-2.96). When examining successfully completed treatment, continued CVD/MI/Stroke 20% following two years 0.79, 0.68-0.91). Conclusion: Patients history remain persistent time. reduces this during well subsequent supporting prolonged therapy.